Abstract

The National Advisory Neurological Diseases and Blindness Council is to be commended for sponsoring this 2-day conference which examined the problems of drug therapy evaluation. The program was planned around 4 half-day sessions, the first of which considered the problems of testing from the point of view of a pharmacologist, a representative of the pharmaceutical industry, a representative of the Food and Drug Administration, and several biostatisticians. The second and third sessions consisted of the meetings of the 8 special panels which considered such items as epilepsy, vertigo, neuralgias and neuropathies, headache, glaucoma and Parkinsonism. The last general session heard reports by the panel chairmen on the results of their deliberations and closed with a summation by Dr. Francis M. Forster, the general chairman. The general outline for testing programs was presented by the biostatisticians and touched on such items as the number of patients needed for a study, double

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.